REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II
Go back to REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 10.72 -0.56 (4.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.28 | 52 Week High | $25.00 | |||
| Open | $11.05 | 52 Week Low | $7.07 | |||
| Day High | $11.39 | P/E | N/A | |||
| Day Low | $10.31 | EPS | $0.00 | |||
| Volume | 1,387,935 | |||||
